SCHEMBL1960667

SCHEMBL1960667

Fc1cccc(F)c1-c1nc2c([nH]1)C=CN(Cc1ccc(Cl)c(Cl)c1)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 3/20 0.38
CLPP Q16740 3/20 0.35
SIGMAR1 Q99720 2/20 0.34
KCNH2 Q12809 1/20 0.34
TMEM97 Q5BJF2 1/20 0.34
KMT2A Q03164 4/20 0.33
MEN1 O00255 2/20 0.33
ATM Q13315 1/20 0.33
RCE1 Q9Y256 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PDE2A O00408 2/20 0.33
PGR P06401 1/20 0.32
PTGES O14684 1/20 0.32
JAK2 O60674 1/20 0.32
HSP90B1 P14625 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1963290 0.88 CSNK1D (0.37) CLPPKCNH2ALDH1A1MAPTPOLB
SCHEMBL1961658 0.87 CXCR2 (0.38) CLPPKMT2AMEN1ALDH1A1MAPT
SCHEMBL1960190 0.85 PGR (0.42) CCR2CLPPSIGMAR1KMT2AMEN1
SCHEMBL1958373 0.82 CNR1 (0.37) CLPPSIGMAR1KMT2AMEN1ATM
SCHEMBL1958832 0.82 ADORA2B (0.34) ALDH1A1POLB
SCHEMBL1959936 0.80 ADORA2B (0.32)
SCHEMBL1960354 0.78 KDM4E (0.36) CLPPSMN1; SMN2
SCHEMBL1962134 0.77 CXCR2 (0.39) CLPPSIGMAR1KMT2AMEN1ALDH1A1
SCHEMBL2345522 0.76 CLPP (0.30) CLPP
SCHEMBL1961662 0.76 ADORA2B (0.34) CLPPALDH1A1HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8779141-B2 Viral inhibitors GILEAD SCIENCES, INC. (US) 2014-07-15 US disclosed
EP-1521754-B1 VIRAL INHIBITORS LEUVEN K U RES & DEV (BE) 2011-08-31 EP disclosed
EP-2332938-A1 Viral inhibitors K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2011-06-15 EP disclosed
US-7737162-B2 Viral inhibitors GILEAD SCIENCES, INC. (US) 2010-06-15 US disclosed
US-20100004281-A1 VIRAL INHIBITORS GILEAD SCIENCES, INC. 2010-01-07 US disclosed
US-20050239821-A1 Viral inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2005-10-27 US disclosed
EP-1521754-A2 VIRAL INHIBITORS K.U.Leuven Research & Development (BE) 2005-04-13 EP disclosed
WO-2004005286-A2 VIRAL INHIBITORS K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004281-A1 VIRAL INHIBITORS ZC3HAV1, MAVS, HAVCR2 CCR2 896/4885CLPP 2023/4885SIGMAR1 4225/4885
US-20050239821-A1 Viral inhibitors ZC3HAV1, ZC3HAV1L, ACE CCR2 1331/4885CLPP 1682/4885SIGMAR1 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.